KANSAS CITY, Mo. -- Suffering from acne can be challenging, and for some, embarrassing.
To help combat the problem, a lot of people will try or pay big bucks for whatever treatment they feel could work. But now, some pharmaceutical companies are being sued for how they marketed and sold one acne prescription product.
The lawsuit claims Medicis Pharmaceutical Corp., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. violated state competition (i.e. antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn off the market. The companies deny this, but two of them are now handing over millions of dollars to settle the matter.
To settle the lawsuit, Impax Laboratories, Inc. agreed to pay $20 million into a Settlement Fund to settle all claims in the lawsuit brought on behalf of consumers and health insurers known as third-party payors. This settlement is in addition to the $23 million settlement recently announced with Medicis Pharmaceutical Corp.
You are only eligible to file a claim if you paid for Solodyn or a generic version between July 23, 2009 and Feb. 25, 2018. If you paid a flat copay for all your prescription drug purchases, whether brand-name or generic, you are not eligible for the settlement. You are also not eligible if you purchased the drug through a Medicaid program. Eligible doses range from 45 mg to 135 mg.
You must submit a Claim Form by July 31, 2018 to be eligible for a payment. The Claim Form, and instructions on how to submit it, are available at www.SolodynCase.com or by calling 1-800-332-7414.
